Exicure (FRA:2H0) E10: €-41.44 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2H0 Exicure Inc FRA:2H0
32 GF Score
Price €1.00
! 3 Warning Signs
View Full Analysis

What is Exicure E10?

Exicure FRA:2H0 +1.02% 32 E10 is €-41.44 as of Jun. 2026. GuruFocus rates FRA:2H0 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Exicure's adjusted earnings per share data for the three months ended in Jun. 2026 was €-0.156. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-41.44 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-21), Exicure's current stock price is €0.995. Exicure's E10 for the quarter that ended in Jun. 2026 was €-41.44. Exicure's Shiller PE Ratio of today is .


Exicure  (FRA:2H0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Exicure E10 Related Terms


Exicure E10 Historical Data

* Premium members only.

The historical data trend for Exicure's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exicure E10 Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Exicure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -41.44

FRA:2H0 vs AEON, LNAI, PBM: E10 Comparison

For the Biotechnology subindustry, Exicure's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exicure Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Exicure's Shiller PE Ratio falls into.


FRA:2H0
32GF Score
Exicure Inc FRA:2H0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exicure E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exicure's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.156/333.9520*333.9520
=-0.156

Current CPI (Jun. 2026) = 333.9520.

Exicure Quarterly Data

per share eps CPI Adj_EPS
201609 -11.944 241.428 -16.521
201612 -20.334 241.432 -28.126
201703 -9.427 243.801 -12.913
201706 -10.097 244.955 -13.765
201709 -6.163 246.819 -8.339
201712 -11.061 246.524 -14.984
201803 -16.986 249.554 -22.731
201806 -21.828 251.989 -28.928
201809 -16.712 252.439 -22.108
201812 -13.185 251.233 -17.526
201903 -15.930 254.202 -20.928
201906 -15.930 256.143 -20.769
201909 -12.258 256.759 -15.943
201912 -18.900 256.974 -24.562
202003 1.357 258.115 1.756
202006 -6.660 257.797 -8.627
202009 -12.735 260.280 -16.340
202012 -17.262 260.474 -22.131
202103 -17.640 264.877 -22.240
202106 -20.169 271.696 -24.790
202109 -34.043 274.310 -41.445
202112 -20.178 278.802 -24.169
202203 -9.398 287.504 -10.916
202206 -7.852 296.311 -8.849
202209 -5.252 296.808 -5.909
202212 19.352 296.797 21.775
202303 -3.269 301.836 -3.617
202306 -3.138 305.109 -3.435
202309 -2.848 307.789 -3.090
202312 -0.605 306.746 -0.659
202403 -0.442 312.332 -0.473
202406 -0.325 314.175 -0.345
202409 -0.514 315.301 -0.544
202412 -3.237 315.605 -3.425
202503 0.453 319.799 0.473
202506 -0.355 322.561 -0.368
202509 -0.332 324.800 -0.341
202512 -0.393 324.054 -0.405
202603 -0.251 330.213 -0.254
202606 -0.156 333.952 -0.156

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-41.44 mean?
Exicure (FRA:2H0) has a E10 of €-41.44 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Exicure and its competitors.
Is Exicure's E10 too high?
Exicure's current E10 is €-41.44. Overall, Exicure has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Exicure's E10 compare to AEON and LNAI?
Exicure's E10 of €-41.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Exicure and its competitors. Exicure's current E10 is €-41.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exicure stock overvalued right now?
Exicure (FRA:2H0) has a current E10 of €-41.44. The current E10 is €-41.44. Exicure's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Exicure (FRA:2H0), the current E10 is €-41.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exicure Business Description

Other Exchanges XCUR:USA2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
32GF Score

Get the complete analysis for FRA:2H0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.00
Price